1. Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy.
- Author
-
Calais J, Morris MJ, Kendi AT, Kalebasty AR, Tutrone R, Anderson MJ, and Sartor O
- Subjects
- Humans, Male, Molecular Targeted Therapy adverse effects, Molecular Targeted Therapy methods, Molecular Targeted Therapy standards, Antigens, Surface metabolism, Glutamate Carboxypeptidase II antagonists & inhibitors, Glutamate Carboxypeptidase II metabolism, Patient Care adverse effects, Patient Care methods, Patient Care standards, Prostatic Neoplasms, Castration-Resistant radiotherapy, Radiopharmaceuticals administration & dosage, Radiopharmaceuticals adverse effects
- Abstract
Optimal patient management protocols for metastatic castration-resistant prostate cancer (mCRPC) are poorly defined and even further complexified with new therapy approvals, such as radiopharmaceuticals. The prostate-specific membrane antigen (PSMA)-targeted agent
177 Lu vipivotide tetraxetan ([177 Lu]Lu-PSMA-617), approved after the phase III VISION study, presents physicians with additional aspects of patient management, including specific adverse event (AE) monitoring and management, as well as radiation safety. Drawing on our experience as VISION study investigators, here we provide guidance on best practices for delivering PSMA-targeted radiopharmaceutical therapy (RPT) to patients with mCRPC. After a comprehensive review of published evidence and guidelines on RPT management in prostate cancer, we identified educational gaps in managing the radiation safety and AEs associated with [177 Lu]Lu-PSMA-617. Our results showed that providing sufficient education on AEs (e.g., fatigue and dry mouth) and radiation safety principles is key to effective delivery and management of patient expectations. Patient counseling by health care professionals, across disciplines, is a cornerstone of optimal patient management during PSMA-targeted RPT. Multidisciplinary collaboration is crucial, and physicians must adhere to radiation safety protocols and counsel patients on radiation safety considerations. Treatment with [177 Lu]Lu-PSMA-617 is generally well tolerated; however, additional interventions may be required, such as dosing modification, medications, or transfusions. Urinary incontinence can be challenging in the context of radiation safety. Multidisciplinary collaboration between medical oncologists and nuclear medicine teams ensures that patients are monitored and managed safely and efficiently. In clinical practice, the benefit-to-risk ratio should always be evaluated on a case-by-case basis., (© 2024 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2024
- Full Text
- View/download PDF